AI Article Synopsis
- * Traditional estrogen therapy can lower the risk of NAFLD but may increase cardiovascular issues, making it unsuitable for this condition.
- * Phytoestrogens emerge as a safer alternative, with potential benefits in treating postmenopausal NAFLD by improving lipid and glucose metabolism, reducing inflammation and oxidative stress, balancing gut bacteria, and preventing liver fibrosis, though their exact mechanisms remain unclear.
Article Abstract
Non-alcoholic fatty liver disease (NAFLD) is a progressive metabolic disease characterized by hepatic steatosis, inflammation, and fibrosis that seriously endangers global public health. Epidemiological studies have shown that the incidence of non-alcoholic fatty liver disease in postmenopausal women has significantly increased. Studies have shown that estrogen deficiency is the main reason for this situation, and supplementing estrogen has become a new direction for preventing the occurrence of postmenopausal fatty liver. However, although classical estrogen replacement therapy can reduce the incidence of postmenopausal NAFLD, it has the risk of increasing stroke and cardiovascular diseases, so it is not suitable for the treatment of postmenopausal NAFLD. More and more recent studies have provided evidence that phytoestrogens are a promising method for the treatment of postmenopausal NAFLD. However, the mechanism of phytoestrogens in preventing and treating postmenopausal NAFLD is still unclear. This paper summarizes the clinical and basic research evidence of phytoestrogens and reviews the potential therapeutic effects of phytoestrogens in postmenopausal NAFLD from six angles: enhancing lipid metabolism in liver and adipose tissue, enhancing glucose metabolism, reducing oxidative stress, reducing the inflammatory response, regulating intestinal flora, and blocking liver fibrosis (Graphical Abstract).
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10502324 | PMC |
| http://dx.doi.org/10.3389/fphar.2023.1237845 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Steatotic liver disease in metastatic breast cancer treated with endocrine therapy and CDK4/6 inhibitor.
Breast Cancer Res Treat
December 2024
Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre University Health Network, 700 University Ave, Toronto, ON, M5G 1Z5, Canada.
Purpose: In early-stage breast cancer, steatotic liver disease (SLD) is associated with increased recurrence, cardiovascular events, and non-cancer death. Endocrine therapy (ET) increases the risk of SLD. The impact of cyclin-dependent kinases 4/6 inhibitors (CDK4/6i) on SLD and prognostic association in metastatic breast cancer is unknown.
View Article and Find Full Text PDFAssociation between menopause, body composition, and nonalcoholic fatty liver disease: A prospective cohort in northern China.
Maturitas
January 2025
Department of Epidemiology and Biostatistics, Institute of Basic Medical Sciences Chinese Academy of Medical Sciences, School of Basic Medicine Peking Union Medical College, 5 Dong Dan San Tiao, Beijing 100005, China; State Key Laboratory of Respiratory Health and Multimorbidity, 5 Dong Dan San Tiao, Beijing 100005, China. Electronic address:
Background: The association between menopause, changes in body composition, and nonalcoholic fatty liver disease is not clear, and there is a lack of weight management strategies for perimenopausal women from the perspective of preventing nonalcoholic fatty liver disease.
Methods: A total of 1316 postmenopausal and 3049 premenopausal women in the Kailuan cohort in China between 2006 and 2017 were enrolled and followed up till 2021. Cox regression models, including the causal mediation analyses, were used to estimate the association between menopause and nonalcoholic fatty liver disease and the potential mediation effect of changes in body composition.
Fatty liver index as an independent predictor of all-cause and disease-specific mortality.
Eur J Gastroenterol Hepatol
December 2024
Department of Public Health, Zhongshan Hospital, Fudan University (Xiamen Branch).
Article Synopsis
- The study evaluates the fatty liver index (FLI) as a noninvasive tool to predict all-cause and specific disease mortality over a 26.25-year follow-up of 11,297 participants.
- Results show that an FLI of 60 or higher is linked to increased risks of death from all causes, cancer, diabetes, and cardiovascular diseases, particularly in females aged 40-60 and individuals who are non-overweight or not abdominally obese.
- The conclusion emphasizes the importance of FLI in assessing mortality risk, highlighting the need for targeted interventions in specific vulnerable groups.
Exploring cytokines dynamics: Uncovering therapeutic concepts for metabolic disorders in postmenopausal women- diabetes, metabolic bone diseases, and non-alcohol fatty liver disease.
Ageing Res Rev
November 2024
Department of Abdominal Oncology, Cancer Center of West China Hospital and Institutes for Systems Genetics, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China. Electronic address:
Menopause is an age-related change that persists for around one-third of a woman's life. Menopause increases the risk of metabolic illnesses such as diabetes, osteoporosis (OP), and nonalcoholic fatty liver disease (NAFLD). Immune mediators (pro-inflammatory cytokines), such as interleukin-1 (IL-1), IL-6, IL-17, transforming growth factor (TGF), and tumor necrosis factor (TNF), exacerbate the challenges of a woman undergoing menopause by causing inflammation and contributing to the development of these metabolic diseases in postmenopausal women.
View Article and Find Full Text PDFDevelopment and validation of a predictive nomogram for the risk of MAFLD in postmenopausal women.
Front Endocrinol (Lausanne)
August 2024
Department of Intensive Care Unit, Changchun Tongyuan Hospital, Changchun, China.
Background And Aim: Metabolic-associated fatty liver disease (MAFLD) has gradually become one of the main health concerns regarding liver diseases. Postmenopausal women represent a high-risk group for MAFLD; therefore, it is of great importance to identify and intervene with patients at risk at an early stage. This study established a predictive nomogram model of MAFLD in postmenopausal women and to enhance the clinical utility of the new model, the researchers limited variables to simple clinical and laboratory indicators that are readily obtainable.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!